GovChime
Notice ID: 897d2a50b032482e95184fdff2a2e01eSolicitation

Call for Submissions for BARDA Other Transaction Prize Vehicle

Archived on August 15, 2023. Original response deadline: . Full description on SAM.gov.

Overview

Response deadline
12:00 PM UTC−04:00
Posted
July 21, 2023
Notice type
Solicitation
NAICS
541714: Research and Development in Biotechnology (except Nanobiotechnology)
Agency
Department of Health and Human ServicesOFFICE OF ASSISTANT SECRETARY FOR PREPAREDNESS AND RESPONSE

Notice details

Office
BARDA - ASPR / DAAPPO / BARDA DCMA
Last updated
Sep 9, 2025

Identifiers

Solicitation number
23-BARDA-PRIZE-VP
Notice ID
897d2a50b032482e95184fdff2a2e01e

Description

**Amendment 1 provides responses to questions received by the July 14, 2023 deadline. The Attachment section has been updated accordingly. Within the Administration for Strategic Preparedness and Response (ASPR), the Biomedical Advanced Research and Development Authority (BARDA) has created a Strategic Plan for 2022- 2026 focused on strengthening the health security of the nation and embracing lessons learned from the COVID-19 pandemic. During the COVID-19 response, BARDA spent considerable resources screening and selecting candidate organizations to make substantial investments in COVID-19 vaccine, therapeutic, diagnostic, and other medical countermeasure (MCM) technology development, reviewing over 4500 market research submissions, conducting close to 700 meetings with potential organizations, and issuing $65 billion in awards to 140 organizations for COVID-19 research and development. While these investments were crucial to receiving Emergency Use Authorization from the Food and Drug Administration for countermeasures and providing hundreds of millions of lifesaving COVID-19 MCMs to the public, multiple approaches were needed to accelerate MCM research and development. This Prize Vehicle seeks to catalyze, in complement traditional contract-based funding mechanisms, the research and development (R&D) and commercialization of MCMs, to meet ambitious goals set by BARDA and other relevant stakeholders including goals in the BARDA Strategic Plan and national initiatives, such as the National Biodefense Strategy and Implementation Plan and Project NextGen. This Prize Vehicle will enable BARDA to establish clear success metrics and offer cash prizes contingent on meeting clear sets of success criteria among competing R&D organizations as well as help to 1) create high visibility to address health security problems, sometimes when the approach or development path is not known 2) increase the diversity and reach of organizations to engage in MCM R&D development and 3) develop solutions that meet bold and ambitious goals that thrive beyond prize award. The resulting awards from the Prize Vehicle will be issued as an Other Transaction, leveraging BARDAs Other Transaction Authority (OTA). BARDA, through this Prize Vehicle, seeks to partner with an organization with the expertise to design, promote, and administer effective prize competitions to catalyze product development and address ambitious BARDA goals. Specifically, BARDA is seeking to partner with an organization who will achieve the following objectives: Design: Work with the government and other stakeholders to design incentive prize competition(s) to catalyze the research and development of products and capabilities to meet ambitious goals set by BARDA Promote: Provide outreach 1) to eligible participant communities (e.g. product developers) to increase diversity of participants or teams of participants; 2) to partnering organizations to increase additional public/private investment and interest; and 3) to the public to raise awareness and create high visibility to address a product development problem or gap Administer: Coordinate and administer the prize competition(s) with BARDA and participants, including awarding of cash prizes and other rewards. Project NextGen seeks to accelerate the development of the next generation of COVID-19 vaccines, therapeutics and enabling technologies including a plan to launch a $50 million international competition to catalyze the development of clinical evidence, regulatory approval and commercialization of patch-based vaccine delivery for a combination vaccine product, such as COVID-19 and seasonal influenza or vaccines for other respiratory pathogens in addition to COVID-19. Patch-based vaccine technologies have the potential to reduce the amount of antigen needed in a safe and effective vaccine dose, reduce cold-chain requirements, improve the experience of vaccination that could drive up adoption rates, and provide added convenience with the potential for self-administration. The first award under the BARDA Prize OT is assumed to design, promote, and administer this competition. The structure of the competition is anticipated to be a first-to-finish competition, consisting of multiple rounds with multiple intermediate finalists and a single final winner thats focused on milestones tied to advanced clinical development, regulatory approval, and/or commercialization. Additional information is available in the attached solicitation.

Full description on SAM.gov

Award Overview

No prior contract identified

No prior award matched this notice's agency, NAICS, place of performance and PSC within 18 months. It may be a new requirement.

Contacts

Documents

No documents available.

Lifecycle

Solicitation:23-BARDA-PRIZE-VP
  1. Solicitation

Award typically follows within 30–90 days after the response deadline. (estimate)

  1. 2×
    SolicitationCurrentJun 30, 2023

    Call for Submissions for BARDA Other Transaction Prize Vehicle

    Notice 897d2a50b032482e95184fdff2a2e01e on SAM.gov

Similar Opportunities

Title
Match
Phase
Deadline
This announcement serves as a reissuance of the BARDA DRIVe EZ-BAA, now known as EZ-BAA-22-100-SOL-00003. This announcement hereby supersedes and replaces prior iterations of the BARDA DRIVe EZ-BAA (e.g. BAA-20-100-SOL-0002). Please reference the attached announcement and applicable amendments for specifics. Additionally, please visit https://drive.hhs.gov/.
68%
Solicitation10/18/2027
This announcement serves as a reissuance of the BARDA DRIVe EZ-BAA, now known as EZ-BAA-22-100-SOL-00003. This announcement hereby supersedes and replaces prior iterations of the BARDA DRIVe EZ-BAA (e.g. BAA-20-100-SOL-0002). Please reference the attached announcement and applicable amendments for specifics. Additionally, please visit https://drive.hhs.gov/.
68%
Solicitation10/18/2027
This announcement serves as a reissuance of the BARDA DRIVe EZ-BAA, now known as EZ-BAA-22-100-SOL-00003. This announcement hereby supersedes and replaces prior iterations of the BARDA DRIVe EZ-BAA (e.g. BAA-20-100-SOL-0002). Please reference the attached announcement and applicable amendments for specifics. Additionally, please visit https://drive.hhs.gov/. _______ Amendment 001: This amendment to the EZBAA hereby opens the following research areas of interest ("AOI"). Please review the amendment for details of each AOI, including closing dates: AOI #15: ReDIRECT AOI #16: Lab at Home AOI #17: Digital MCMs AOI #18: Host-Directed Therapeutics AOI #19: Healing Lungs AOI #20: DRIVe Forward AOI #21: Vaccines on Demand AOI #22: ReBooT AOI #23: Host-Based Diagnostics _____
68%
Solicitation10/18/2027
This announcement serves as a reissuance of the BARDA DRIVe EZ-BAA, now known as EZ-BAA-22-100-SOL-00003. This announcement hereby supersedes and replaces prior iterations of the BARDA DRIVe EZ-BAA (e.g. BAA-20-100-SOL-0002). Please reference the attached announcement and applicable amendments for specifics. Additionally, please visit https://drive.hhs.gov/. _______ Amendment 001: This amendment to the EZBAA hereby opens the following research areas of interest ("AOI"). Please review the amendment for details of each AOI, including closing dates: AOI #15: ReDIRECT AOI #16: Lab at Home AOI #17: Digital MCMs AOI #18: Host-Directed Therapeutics AOI #19: Healing Lungs AOI #20: DRIVe Forward AOI #21: Vaccines on Demand AOI #22: ReBooT AOI #23: Host-Based Diagnostics _____ 11/8/22 - Please see Amendment 002 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 1. Adding the the following Area of Interest (AOI): AOI #24: REPAIR 2. Clarifying an adminstrative error. _____ 11/14/22 - Please see Amendment 003 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 1. Revising the following Area of Interest (AOI): AOI #19: Healing Lungs _____ 12/15/22 - Please see Amendment 004 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 1. Updating the closing date for the following Area of Interest (AOI): AOI #21: Vaccines on Demand ______ 1/11/23 - Please see Amendment 005 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 1. Pausing the following Area of Interest (AOI) by establishing a new closing date of February 15, 2023 at 12:00PM ET: AOI #15: ReDIRECT ______ 2/1/23 - Please see Amendment 006 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 1. Updating the closing date for the following Area of Interest (AOI): AOI #19: Healing Lungs 2. Updating the closing date for the following Area of Interest (AOI): AOI #17: Digital MCMs 3. Updating the closing date for the following Area of Interest (AOI): AOI #16: Lab at Home 4. Revising the following Area of Interest (AOI): AOI #16: Lab at Home ______ 2/3/23 - Please see Amendment 007 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 1. Updating the closing date for the following Area of Interest (AOI): AOI #24: REPAIR ______ 5/1/23 - Please see Amendment 008 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 1. Adding the following Area of Interest (AOI): AOI #25: FASTx 2. Updating the language in Section III (F) of the Easy Broad Agency Announcement titled “Plus (+) Phase”. ______ 5/18/23 - Please see Amendment 009 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 1. Reopening the following Area of Interest (AOI), which is reopened to support project Next Gen: AOI #21: Vaccines on Demand ______ 5/25/23 - Please see Amendment 010 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 1. Revising the following Area of Interest (AOI): AOI #24: REPAIR 2. Updating the closing date for the following Area of Interest (AOI): AOI #24: REPAIR ______ 6/27/23 - Please see Amendment 011 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 1. Closing the following Area of Interest (AOI): AOI #18: Host-Directed Therapeutics 2. Closing the following Area of Interest (AOI): AOI #23: Host-Based Diagnostics 3. Updating the closing date for the following Area of Interest (AOI): AOI #19: Healing Lungs ______ 9/13/23 - Please see Amendment 012 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 1. Updating the closing date for the following Area of Interest (AOI): AOI #16: Lab at Home 2. Updating the closing date for the following Area of Interest (AOI): AOI #17: Digital MCMs 3. Updating the closing date for the following Area of Interest (AOI): AOI #19: Healing Lungs 4. Revising the following Area of Interest (AOI): AOI #16 Lab at Home 5. Adding the following Area of Interest (AOI): AOI #26: Agnostic Diagnostic _______ 9/14/23 - Please see Amendment 013 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 1. Pausing the following Area of Interest (AOI): AOI #20: DRIVe Forward ________ 9/26/23 - Please see Amendment 014 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 1. Pausing the following Area of Interest (AOI): AOI #21: Vaccines on Demand _________ 10/26/23 - Please see Amendment 015 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 1. Updating the closing date for the following Area of Interest (AOI): AOI #22: ReBoot 2. Updating the closing date for the following Area of Interest (AOI): AOI #25: FASTx 3. Revising the following Area of Interest (AOI): AOI #22: ReBoot 4. Revising the following Area of Interest (AOI): AOI #25: FASTx ___________ 10/30/23 - Please see Amendment 016 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 1. Pausing the following Area of Interest (AOI): AOI #24: REPAIR __________ 11/15/23 - Please see Amendment 017 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 1. Reopening the following Area of Interest (AOI): AOI #20: DRIVe Forward 2. Revising the following Area of Interest (AOI): AOI #20: DRIVe Forward __________ 12/13/23 - Please see Amendment 018 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 1. Updating the closing date for the following Area of Interest (AOI): AOI #16: Lab at Home 2. Revising the following Area of Interest (AOI): AOI #16: Lab at Home 3. Pausing the following Area of Interest (AOI): AOI #17: Digital MCMs 4. Updating the closing date for the following Area of Interest (AOI): AOI #19: Healing Lungs __________ 01/03/24 - Please see Amendment 019 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 1. Reopening the following Area of Interest (AOI): AOI #15: ReDIRECT 2. Revising the following Area of Interest (AOI): AOI #15: ReDIRECT __________ 01/10/24 - Please see Amendment 020 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 1. Pausing the following Area of Interest (AOI): AOI #26: Agnostic Diagnostic 2. Adding a topic to the following Area of Interest (AOI): AOI #20: DRIVe Forward 3. Updating the closing date for the following Area of Interest (AOI): AOI #20: DRIVe Forward _________ 01/18/24 - Please see Amendment 021 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 1. Adding the following Area of Interest (AOI): AOI #27: Stopping Secondary Spread __________ 2/5/24 - Please see Amendment 022 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 1. Pausing the following research Area of Interest (AOI): AOI #27: Stopping Secondary Spread 2. Revise topics for the following research Area of Interest (AOI): AOI #20: DRIVe Forward __________ 02/12/24 - Please see Amendment 023 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 1. Reopening the following Area of Interest (AOI): AOI #26: Agnostic Diagnostic __________ 02/21/24 - Please see Amendment 024 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 1. Updating the closing date for the following Area of Interest (AOI): AOI #22: ReBooT 2. Updating the closing date for the following Area of Interest (AOI): AOI #25: FASTx __________ 03/04/24 - Please see Amendment 025 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 1. Reopening the following Area of Interest (AOI): AOI #24: RePAIR 2. Revising the following Area of Interest (AOI): AOI #24: RePAIR __________ 03/12/24 - Please see Amendment 026 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 1. Updating the closing date for the following Area of Interest (AOI): AOI #16: Lab at Home 2. Updating the closing date for the following Area of Interest (AOI): AOI #19: Healing Lungs _________ 04/22/24 - Please see Amendment 027 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 1. Reopening the following Area of Interest (AOI): AOI #20: DRIVe Forward 2. Removing two topic areas and adding one topic area to the following Area of Interest (AOI): AOI #20: DRIVe Forward _________ 05/01/24 - Please see Amendment 028 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 1. Updating the closing date for the following Area of Interest (AOI): AOI #15: ReDIRECT 2. Updating the closing date for the following Area of Interest (AOI): AOI #26: Agnostic Diagnostic 3. Reopening the following Area of Interest (AOI): AOI #17: Digital MCMs 4. Revising the following Area of Interest (AOI): AOI #17: Digital MCMs __________ 05/09/24 - Please see Amendment 029 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 1. Pausing the following Area of Interest (AOI): AOI #16: Lab at Home 2. Updating the closing date for the following Area of Interest (AOI): AOI #19: Healing Lungs 3. Revising the following Area of Interest (AOI): AOI #19: Healing Lungs 4. Updating the closing date for the following Area of Interest (AOI): AOI #24: RePAIR _________ 09/24/24 - Please see Amendment 030 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 1. Adding the following Area of Interest (AOI): AOI #28: Influenza Vaccine Innovation 2. Pausing the following Area of Interest (AOI): AOI #26: Agnostic Diagnostic ___________ 09/30/24 - Please see Amendment 031 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 1. Reopening the following Area of Interest (AOI): AOI #24: RePAIR ___________ 10/10/24 - Please see Amendment 032 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: Update the closing date for the following Area of Interest (AOI): AOI #19: Healing Lungs Pause the following Area of Interest (AOI) on 10/31/24: AOI #17: Digital MCMs ___________ 10/31/24 - Please see Amendment 033 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: Reopen the following Area of Interest (AOI) on 11/1/24: AOI #15: ReDIRECT 2. Remove language requiring a Rough Order of Magnitude (ROM) from the record 11/26/2024 - Please see Amendment 034 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 1) Reopen the following Area of Interest (AOI): AOI #22: ReBooT 2) Revise the following Area of Interest (AOI): AOI #22: ReBooT 3) Pause the following Area of Interest (AOI): AOI#24: RePAIR ___________ 1/13/2025 - Please see Amendment 035 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: 1) Reopen the following Area of Interest (AOI) on 1/15/2025: AOI #16: Lab at Home 2) Open the following Area of Interest (AOI): AOI #29: Type to Treat ___________ 2/14/2025 - Please see Amendment 036 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this Amendment, BARDA is: Updating the closing date for the following Area of Interest (AOI): AOI #19: Healing Lung __________ 4/22/2025 - Please see Amendment 037 for Easy Broad Agency Announcement (EZ-BAA) EZ-BAA-22-100-SOL-00003. Under this amendment, BARDA is revising the following Areas of Interest (AOI) to close effective immediately: AOI #19: Healing Lungs AOI #22: ReBooT AOI #29: Type to Treat Additional details can be found in the corresponding Amendment 037.
67%
Solicitation10/18/2027
We appreciate your interest in partnering with BARDA. The latest BARDA Broad Agency Announcement (BAA) is Amendment 7 posted on March 19, 2026. All contracting-related inquiries should be sent to BARDA-BAA@hhs.gov. The final proposal submission deadline is September 25, 2028, at 4:30 PM Eastern Time for open areas of interest.
66%
Solicitation09/25/2028

Additional Details

Solicitation Number

23-BARDA-PRIZE-VP

Archive Date

Aug 15, 2023

Office Address

WASHINGTON, DC, 20515